Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model

Proceedings of the National Academy of Sciences of the United States of America

Volumn 113, Issue 15, 2016, Pages E2172-E2179

  Silva, Aleidy ^a   Lee, Bai Yu ^b   Clemens, Daniel L ^b   Kee, Theodore ^a   Ding, Xianting ^c   Ho, Chih Ming ^a   Horwitz, Marcus A ^b  

^a Department of Civil and Environmental Engineering   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Drug combination optimization; Feedback system control; Mycobacterium tuberculosis; Tuberculosis

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; GREEN FLUORESCENT PROTEIN; ISONIAZID; ISOPROPYL THIOGALACTOSIDE; LINEZOLID; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PRETOMANID; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; DRUG COMBINATION;

ARTICLE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEEDBACK SYSTEM; FLUORESCENCE; HUMAN; HUMAN CELL; MACROPHAGE CULTURE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; CELL CULTURE; CELL LINE; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; GENETICS; HIGH THROUGHPUT SCREENING; MACROPHAGE; MICROBIOLOGY;

ANTITUBERCULAR AGENTS; CELL LINE; CELLS, CULTURED; DRUG COMBINATIONS; DRUG INTERACTIONS; FEEDBACK; GREEN FLUORESCENT PROTEINS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; ISOPROPYL THIOGALACTOSIDE; MACROPHAGES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 84963753977     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1600812113     Document Type: Article

References (20)

1. WHO (2014) Global Tuberculosis Report 2014. Available at apps.who.int/iris/bitstream/10665/137094/1/9789241564809-eng.pdf?ua=1. Accessed June 5, 2015.
2. Institute of Medicine (US) Forum on Drug Discovery D and Translation (2013) Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary (National Academies Press, Washington, DC).
3. Spigelman MK (2007) New tuberculosis therapeutics: A growing pipeline. J Infect Dis 196(Suppl 1):S28-S34.
4. Zumla A, et al. (2015) Tuberculosis treatment and management-an update on treatment regimens, trials, new drugs, and adjunct therapies. Lancet Respir Med 3(3):220-234.
5. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X (2010) Global tuberculosis drug development pipeline: The need and the reality. Lancet 375(9731):2100-2109.
6. Nuermberger EL, Spigelman MK, Yew WW (2010) Current development and future prospects in chemotherapy of tuberculosis. Respirology 15(5):764-778.
7. Ding X, et al. (2014) Discovery of a low order drug-cell response surface for applications in personalized medicine. Phys Biol 11(6):065003.
8. Wong PK, et al. (2008) Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm. Proc Natl Acad Sci USA 105(13):5105-5110.
9. Valamehr B, Tsutsui H, Ho CM, Wu H (2011) Developing defined culture systems for human pluripotent stem cells. Regen Med 6(5):623-634.
10. Al-Shyoukh I, et al. (2011) Systematic quantitative characterization of cellular responses induced by multiple signals. BMC Syst Biol 5:88.
11. Wang H, et al. (2015) Mechanism-independent optimization of combinatorial nanodiamond and unmodified drug delivery using a phenotypically driven platform technology. ACS Nano 9(3):3332-3344.
12. Ding X, et al. (2012) Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity. Int J Nanomedicine 7:2281-2292.
13. Weiss A, et al. (2015) A streamlined search technology for identification of synergistic drug combinations. Sci Rep 5:14508.
14. Lee BY, Clemens DL, Horwitz MA (2008) The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages. Mol Microbiol 68(4):1047-1060.
15. Jaynes J, Ding X, Xu H, Wong WK, Ho CM (2013) Application of fractional factorial designs to study drug combinations. Stat Med 32(2):307-318.
16. Xu H, Jaynes J, Ding X (2014) Combining two-level and three-level orthogonal arrays for factor screening and response surface exploration. Stat Sin 24(1):269-289.
17. Tyagi S, et al. (2015) Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 112(3):869-874.
18. Grosset JH, et al. (2013) Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 188(5):608-612.
19. Dickinson JM, Aber VR, Mitchison DA (1977) Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium tuberculosis. Am Rev Respir Dis 116(4):627-635.
20. Almeida D, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampinpyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53(10):4178-4184.